<?xml version="1.0"?>
<rss version="2.0">
 <channel>
  <title>StreetInsider.com News Articles</title>
  <link>http://www.streetinsider.com</link>
  <description>Latest StreetInsider.com News Articles</description>
  <language>en-us</language>
  <copyright>Copyright 2026, StreetInsider.com</copyright>
  <managingEditor>rss@streetinsider.com (SI RSS)</managingEditor>
  <webMaster>rss@streetinsider.com (SI RSS)</webMaster>
  <lastBuildDate>Thu, 21 May 2026 18:01:00 -0400</lastBuildDate>
  <docs>http://blogs.law.harvard.edu/tech/rss</docs>
  <image>
   <url>http://www.streetinsider.com/images/rss_logo.gif</url>
   <title>StreetInsider.com News Articles</title>
   <link>http://www.streetinsider.com</link>
   <width>143</width>
   <height>28</height>
  </image>
  <skipHours>
   <hour>0</hour>
   <hour>1</hour>
   <hour>2</hour>
   <hour>3</hour>
   <hour>21</hour>
   <hour>22</hour>
   <hour>23</hour>
  </skipHours>
  <skipDays>
   <day>Saturday</day>
   <day>Sunday</day>
  </skipDays>
  <item>
   <title>Fennec Pharmaceuticals Announces New Research Supporting Integration and Use of PEDMARK® at the 2026 ASCO Annual Meeting</title>
   <link>http://www.streetinsider.com/Press+Releases/Fennec+Pharmaceuticals+Announces+New+Research+Supporting+Integration+and+Use+of+PEDMARK%C2%AE+at+the+2026+ASCO+Annual+Meeting/26537185.html</link>
   <description>
&lt;p align=&quot;center&quot;&gt;&lt;em&gt;~&lt;/em&gt;&lt;em&gt; Growing Independent Research Efforts are Expanding Evidence Base Around How PEDMARK&lt;/em&gt;&lt;em&gt;®&lt;/em&gt;&lt;em&gt; (sodium thiosulfate injection) May Benefit Broader and More Diverse Patient Populations &lt;/em&gt;&lt;em&gt;~&lt;/em&gt;&lt;/p&gt;  &lt;p align=&quot;center&quot;&gt;&lt;em&gt;~ &lt;/em&gt;&lt;em&gt;Real-World Evidence Shows Administration of PEDMARK&lt;/em&gt;&lt;em&gt;®&lt;/em&gt;&lt;em&gt; Approximately Six Hours After Cisplatin Can Be Safe &amp;amp; Easily Integrated into Patient Care and Does Not Compromise Cisplatin’s Established Antitumor Activity &lt;/em&gt;&lt;em&gt;~&lt;/em&gt;&lt;/p&gt;  &lt;p align=&quot;justify&quot;&gt;RESEARCH TRIANGLE PARK, N.C., May  21, 2026  (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, today announced that new research evaluating PEDMARK® (sodium thiosulfate injection) across multiple patient populations and tumor types will be shared as</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/Fennec+Pharmaceuticals+Announces+New+Research+Supporting+Integration+and+Use+of+PEDMARK%C2%AE+at+the+2026+ASCO+Annual+Meeting/26537185.html</guid>
   <pubDate>Thu, 21 May 2026 18:01:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.06822034</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.17568519</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.50200982</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.50208664</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.50214646</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.50216726</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.60012004</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">FENC</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">FRX</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00081842</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00474218</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00786879</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.01304637</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.20026344</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.21047090</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.21157671</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.21612337</category>
   	  </item>
  <item>
   <title>Fennec Pharmaceuticals Announces New Research Supporting Integration and Use of PEDMARK® at the 2026 ASCO Annual Meeting</title>
   <link>http://www.streetinsider.com/Press+Releases/Fennec+Pharmaceuticals+Announces+New+Research+Supporting+Integration+and+Use+of+PEDMARK%C2%AE+at+the+2026+ASCO+Annual+Meeting/26537185.html</link>
   <description>
&lt;p align=&quot;center&quot;&gt;&lt;em&gt;~&lt;/em&gt;&lt;em&gt; Growing Independent Research Efforts are Expanding Evidence Base Around How PEDMARK&lt;/em&gt;&lt;em&gt;®&lt;/em&gt;&lt;em&gt; (sodium thiosulfate injection) May Benefit Broader and More Diverse Patient Populations &lt;/em&gt;&lt;em&gt;~&lt;/em&gt;&lt;/p&gt;  &lt;p align=&quot;center&quot;&gt;&lt;em&gt;~ &lt;/em&gt;&lt;em&gt;Real-World Evidence Shows Administration of PEDMARK&lt;/em&gt;&lt;em&gt;®&lt;/em&gt;&lt;em&gt; Approximately Six Hours After Cisplatin Can Be Safe &amp;amp; Easily Integrated into Patient Care and Does Not Compromise Cisplatin’s Established Antitumor Activity &lt;/em&gt;&lt;em&gt;~&lt;/em&gt;&lt;/p&gt;  &lt;p align=&quot;justify&quot;&gt;RESEARCH TRIANGLE PARK, N.C., May  21, 2026  (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, today announced that new research evaluating PEDMARK® (sodium thiosulfate injection) across multiple patient populations and tumor types will be shared as</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/Fennec+Pharmaceuticals+Announces+New+Research+Supporting+Integration+and+Use+of+PEDMARK%C2%AE+at+the+2026+ASCO+Annual+Meeting/26537185.html</guid>
   <pubDate>Thu, 21 May 2026 18:01:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.06822034</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.17568519</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.50200982</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.50208664</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.50214646</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.50216726</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.60012004</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">FENC</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">FRX</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00081842</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00474218</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00786879</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.01304637</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.20026344</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.21047090</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.21157671</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.21612337</category>
   	  </item>
  <item>
   <title>Fennec Pharmaceuticals Announces New Research Supporting Integration and Use of PEDMARK® at the 2026 ASCO Annual Meeting</title>
   <link>http://www.streetinsider.com/Press+Releases/Fennec+Pharmaceuticals+Announces+New+Research+Supporting+Integration+and+Use+of+PEDMARK%C2%AE+at+the+2026+ASCO+Annual+Meeting/26537185.html</link>
   <description>
&lt;p align=&quot;center&quot;&gt;&lt;em&gt;~&lt;/em&gt;&lt;em&gt; Growing Independent Research Efforts are Expanding Evidence Base Around How PEDMARK&lt;/em&gt;&lt;em&gt;®&lt;/em&gt;&lt;em&gt; (sodium thiosulfate injection) May Benefit Broader and More Diverse Patient Populations &lt;/em&gt;&lt;em&gt;~&lt;/em&gt;&lt;/p&gt;  &lt;p align=&quot;center&quot;&gt;&lt;em&gt;~ &lt;/em&gt;&lt;em&gt;Real-World Evidence Shows Administration of PEDMARK&lt;/em&gt;&lt;em&gt;®&lt;/em&gt;&lt;em&gt; Approximately Six Hours After Cisplatin Can Be Safe &amp;amp; Easily Integrated into Patient Care and Does Not Compromise Cisplatin’s Established Antitumor Activity &lt;/em&gt;&lt;em&gt;~&lt;/em&gt;&lt;/p&gt;  &lt;p align=&quot;justify&quot;&gt;RESEARCH TRIANGLE PARK, N.C., May  21, 2026  (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, today announced that new research evaluating PEDMARK® (sodium thiosulfate injection) across multiple patient populations and tumor types will be shared as</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/Fennec+Pharmaceuticals+Announces+New+Research+Supporting+Integration+and+Use+of+PEDMARK%C2%AE+at+the+2026+ASCO+Annual+Meeting/26537185.html</guid>
   <pubDate>Thu, 21 May 2026 18:01:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.06822034</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.17568519</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.50200982</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.50208664</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.50214646</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.50216726</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.60012004</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">FENC</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">FRX</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00081842</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00474218</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00786879</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.01304637</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.20026344</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.21047090</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.21157671</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.21612337</category>
   	  </item>
  <item>
   <title>Fennec Pharmaceuticals Announces New Research Supporting Integration and Use of PEDMARK® at the 2026 ASCO Annual Meeting</title>
   <link>http://www.streetinsider.com/Press+Releases/Fennec+Pharmaceuticals+Announces+New+Research+Supporting+Integration+and+Use+of+PEDMARK%C2%AE+at+the+2026+ASCO+Annual+Meeting/26537185.html</link>
   <description>
&lt;p align=&quot;center&quot;&gt;&lt;em&gt;~&lt;/em&gt;&lt;em&gt; Growing Independent Research Efforts are Expanding Evidence Base Around How PEDMARK&lt;/em&gt;&lt;em&gt;®&lt;/em&gt;&lt;em&gt; (sodium thiosulfate injection) May Benefit Broader and More Diverse Patient Populations &lt;/em&gt;&lt;em&gt;~&lt;/em&gt;&lt;/p&gt;  &lt;p align=&quot;center&quot;&gt;&lt;em&gt;~ &lt;/em&gt;&lt;em&gt;Real-World Evidence Shows Administration of PEDMARK&lt;/em&gt;&lt;em&gt;®&lt;/em&gt;&lt;em&gt; Approximately Six Hours After Cisplatin Can Be Safe &amp;amp; Easily Integrated into Patient Care and Does Not Compromise Cisplatin’s Established Antitumor Activity &lt;/em&gt;&lt;em&gt;~&lt;/em&gt;&lt;/p&gt;  &lt;p align=&quot;justify&quot;&gt;RESEARCH TRIANGLE PARK, N.C., May  21, 2026  (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, today announced that new research evaluating PEDMARK® (sodium thiosulfate injection) across multiple patient populations and tumor types will be shared as</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/Fennec+Pharmaceuticals+Announces+New+Research+Supporting+Integration+and+Use+of+PEDMARK%C2%AE+at+the+2026+ASCO+Annual+Meeting/26537185.html</guid>
   <pubDate>Thu, 21 May 2026 18:01:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.06822034</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.17568519</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.50200982</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.50208664</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.50214646</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.50216726</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.60012004</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">FENC</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">FRX</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00081842</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00474218</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00786879</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.01304637</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.20026344</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.21047090</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.21157671</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.21612337</category>
   	  </item>
  <item>
   <title>Fennec Pharmaceuticals Announces New Research Supporting Integration and Use of PEDMARK® at the 2026 ASCO Annual Meeting</title>
   <link>http://www.streetinsider.com/Press+Releases/Fennec+Pharmaceuticals+Announces+New+Research+Supporting+Integration+and+Use+of+PEDMARK%C2%AE+at+the+2026+ASCO+Annual+Meeting/26537185.html</link>
   <description>
&lt;p align=&quot;center&quot;&gt;&lt;em&gt;~&lt;/em&gt;&lt;em&gt; Growing Independent Research Efforts are Expanding Evidence Base Around How PEDMARK&lt;/em&gt;&lt;em&gt;®&lt;/em&gt;&lt;em&gt; (sodium thiosulfate injection) May Benefit Broader and More Diverse Patient Populations &lt;/em&gt;&lt;em&gt;~&lt;/em&gt;&lt;/p&gt;  &lt;p align=&quot;center&quot;&gt;&lt;em&gt;~ &lt;/em&gt;&lt;em&gt;Real-World Evidence Shows Administration of PEDMARK&lt;/em&gt;&lt;em&gt;®&lt;/em&gt;&lt;em&gt; Approximately Six Hours After Cisplatin Can Be Safe &amp;amp; Easily Integrated into Patient Care and Does Not Compromise Cisplatin’s Established Antitumor Activity &lt;/em&gt;&lt;em&gt;~&lt;/em&gt;&lt;/p&gt;  &lt;p align=&quot;justify&quot;&gt;RESEARCH TRIANGLE PARK, N.C., May  21, 2026  (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, today announced that new research evaluating PEDMARK® (sodium thiosulfate injection) across multiple patient populations and tumor types will be shared as</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/Fennec+Pharmaceuticals+Announces+New+Research+Supporting+Integration+and+Use+of+PEDMARK%C2%AE+at+the+2026+ASCO+Annual+Meeting/26537185.html</guid>
   <pubDate>Thu, 21 May 2026 18:01:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.06822034</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.17568519</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.50200982</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.50208664</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.50214646</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.50216726</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.60012004</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">FENC</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">FRX</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00081842</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00474218</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00786879</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.01304637</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.20026344</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.21047090</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.21157671</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.21612337</category>
   	  </item>
  <item>
   <title>Fennec Pharmaceuticals Announces New Research Supporting Integration and Use of PEDMARK® at the 2026 ASCO Annual Meeting</title>
   <link>http://www.streetinsider.com/Press+Releases/Fennec+Pharmaceuticals+Announces+New+Research+Supporting+Integration+and+Use+of+PEDMARK%C2%AE+at+the+2026+ASCO+Annual+Meeting/26537185.html</link>
   <description>
&lt;p align=&quot;center&quot;&gt;&lt;em&gt;~&lt;/em&gt;&lt;em&gt; Growing Independent Research Efforts are Expanding Evidence Base Around How PEDMARK&lt;/em&gt;&lt;em&gt;®&lt;/em&gt;&lt;em&gt; (sodium thiosulfate injection) May Benefit Broader and More Diverse Patient Populations &lt;/em&gt;&lt;em&gt;~&lt;/em&gt;&lt;/p&gt;  &lt;p align=&quot;center&quot;&gt;&lt;em&gt;~ &lt;/em&gt;&lt;em&gt;Real-World Evidence Shows Administration of PEDMARK&lt;/em&gt;&lt;em&gt;®&lt;/em&gt;&lt;em&gt; Approximately Six Hours After Cisplatin Can Be Safe &amp;amp; Easily Integrated into Patient Care and Does Not Compromise Cisplatin’s Established Antitumor Activity &lt;/em&gt;&lt;em&gt;~&lt;/em&gt;&lt;/p&gt;  &lt;p align=&quot;justify&quot;&gt;RESEARCH TRIANGLE PARK, N.C., May  21, 2026  (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, today announced that new research evaluating PEDMARK® (sodium thiosulfate injection) across multiple patient populations and tumor types will be shared as</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/Fennec+Pharmaceuticals+Announces+New+Research+Supporting+Integration+and+Use+of+PEDMARK%C2%AE+at+the+2026+ASCO+Annual+Meeting/26537185.html</guid>
   <pubDate>Thu, 21 May 2026 18:01:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.06822034</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.17568519</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.50200982</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.50208664</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.50214646</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.50216726</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.60012004</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">FENC</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">FRX</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00081842</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00474218</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00786879</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.01304637</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.20026344</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.21047090</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.21157671</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.21612337</category>
   	  </item>
  <item>
   <title>Fennec Pharmaceuticals Announces New Research Supporting Integration and Use of PEDMARK® at the 2026 ASCO Annual Meeting</title>
   <link>http://www.streetinsider.com/Press+Releases/Fennec+Pharmaceuticals+Announces+New+Research+Supporting+Integration+and+Use+of+PEDMARK%C2%AE+at+the+2026+ASCO+Annual+Meeting/26537185.html</link>
   <description>
&lt;p align=&quot;center&quot;&gt;&lt;em&gt;~&lt;/em&gt;&lt;em&gt; Growing Independent Research Efforts are Expanding Evidence Base Around How PEDMARK&lt;/em&gt;&lt;em&gt;®&lt;/em&gt;&lt;em&gt; (sodium thiosulfate injection) May Benefit Broader and More Diverse Patient Populations &lt;/em&gt;&lt;em&gt;~&lt;/em&gt;&lt;/p&gt;  &lt;p align=&quot;center&quot;&gt;&lt;em&gt;~ &lt;/em&gt;&lt;em&gt;Real-World Evidence Shows Administration of PEDMARK&lt;/em&gt;&lt;em&gt;®&lt;/em&gt;&lt;em&gt; Approximately Six Hours After Cisplatin Can Be Safe &amp;amp; Easily Integrated into Patient Care and Does Not Compromise Cisplatin’s Established Antitumor Activity &lt;/em&gt;&lt;em&gt;~&lt;/em&gt;&lt;/p&gt;  &lt;p align=&quot;justify&quot;&gt;RESEARCH TRIANGLE PARK, N.C., May  21, 2026  (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, today announced that new research evaluating PEDMARK® (sodium thiosulfate injection) across multiple patient populations and tumor types will be shared as</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/Fennec+Pharmaceuticals+Announces+New+Research+Supporting+Integration+and+Use+of+PEDMARK%C2%AE+at+the+2026+ASCO+Annual+Meeting/26537185.html</guid>
   <pubDate>Thu, 21 May 2026 18:01:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.06822034</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.17568519</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.50200982</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.50208664</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.50214646</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.50216726</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.60012004</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">FENC</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">FRX</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00081842</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00474218</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00786879</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.01304637</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.20026344</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.21047090</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.21157671</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.21612337</category>
   	  </item>
  <item>
   <title>Fennec Pharmaceuticals Announces New Research Supporting Integration and Use of PEDMARK® at the 2026 ASCO Annual Meeting</title>
   <link>http://www.streetinsider.com/Press+Releases/Fennec+Pharmaceuticals+Announces+New+Research+Supporting+Integration+and+Use+of+PEDMARK%C2%AE+at+the+2026+ASCO+Annual+Meeting/26537185.html</link>
   <description>
&lt;p align=&quot;center&quot;&gt;&lt;em&gt;~&lt;/em&gt;&lt;em&gt; Growing Independent Research Efforts are Expanding Evidence Base Around How PEDMARK&lt;/em&gt;&lt;em&gt;®&lt;/em&gt;&lt;em&gt; (sodium thiosulfate injection) May Benefit Broader and More Diverse Patient Populations &lt;/em&gt;&lt;em&gt;~&lt;/em&gt;&lt;/p&gt;  &lt;p align=&quot;center&quot;&gt;&lt;em&gt;~ &lt;/em&gt;&lt;em&gt;Real-World Evidence Shows Administration of PEDMARK&lt;/em&gt;&lt;em&gt;®&lt;/em&gt;&lt;em&gt; Approximately Six Hours After Cisplatin Can Be Safe &amp;amp; Easily Integrated into Patient Care and Does Not Compromise Cisplatin’s Established Antitumor Activity &lt;/em&gt;&lt;em&gt;~&lt;/em&gt;&lt;/p&gt;  &lt;p align=&quot;justify&quot;&gt;RESEARCH TRIANGLE PARK, N.C., May  21, 2026  (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, today announced that new research evaluating PEDMARK® (sodium thiosulfate injection) across multiple patient populations and tumor types will be shared as</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/Fennec+Pharmaceuticals+Announces+New+Research+Supporting+Integration+and+Use+of+PEDMARK%C2%AE+at+the+2026+ASCO+Annual+Meeting/26537185.html</guid>
   <pubDate>Thu, 21 May 2026 18:01:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.06822034</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.17568519</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.50200982</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.50208664</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.50214646</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.50216726</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.60012004</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">FENC</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">FRX</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00081842</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00474218</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00786879</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.01304637</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.20026344</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.21047090</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.21157671</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.21612337</category>
   	  </item>
  <item>
   <title>Fennec Pharmaceuticals Announces New Research Supporting Integration and Use of PEDMARK® at the 2026 ASCO Annual Meeting</title>
   <link>http://www.streetinsider.com/Press+Releases/Fennec+Pharmaceuticals+Announces+New+Research+Supporting+Integration+and+Use+of+PEDMARK%C2%AE+at+the+2026+ASCO+Annual+Meeting/26537185.html</link>
   <description>
&lt;p align=&quot;center&quot;&gt;&lt;em&gt;~&lt;/em&gt;&lt;em&gt; Growing Independent Research Efforts are Expanding Evidence Base Around How PEDMARK&lt;/em&gt;&lt;em&gt;®&lt;/em&gt;&lt;em&gt; (sodium thiosulfate injection) May Benefit Broader and More Diverse Patient Populations &lt;/em&gt;&lt;em&gt;~&lt;/em&gt;&lt;/p&gt;  &lt;p align=&quot;center&quot;&gt;&lt;em&gt;~ &lt;/em&gt;&lt;em&gt;Real-World Evidence Shows Administration of PEDMARK&lt;/em&gt;&lt;em&gt;®&lt;/em&gt;&lt;em&gt; Approximately Six Hours After Cisplatin Can Be Safe &amp;amp; Easily Integrated into Patient Care and Does Not Compromise Cisplatin’s Established Antitumor Activity &lt;/em&gt;&lt;em&gt;~&lt;/em&gt;&lt;/p&gt;  &lt;p align=&quot;justify&quot;&gt;RESEARCH TRIANGLE PARK, N.C., May  21, 2026  (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, today announced that new research evaluating PEDMARK® (sodium thiosulfate injection) across multiple patient populations and tumor types will be shared as</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/Fennec+Pharmaceuticals+Announces+New+Research+Supporting+Integration+and+Use+of+PEDMARK%C2%AE+at+the+2026+ASCO+Annual+Meeting/26537185.html</guid>
   <pubDate>Thu, 21 May 2026 18:01:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.06822034</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.17568519</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.50200982</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.50208664</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.50214646</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.50216726</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.60012004</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">FENC</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">FRX</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00081842</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00474218</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00786879</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.01304637</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.20026344</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.21047090</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.21157671</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.21612337</category>
   	  </item>
  <item>
   <title>Fennec Pharmaceuticals Announces New Research Supporting Integration and Use of PEDMARK® at the 2026 ASCO Annual Meeting</title>
   <link>http://www.streetinsider.com/Press+Releases/Fennec+Pharmaceuticals+Announces+New+Research+Supporting+Integration+and+Use+of+PEDMARK%C2%AE+at+the+2026+ASCO+Annual+Meeting/26537185.html</link>
   <description>
&lt;p align=&quot;center&quot;&gt;&lt;em&gt;~&lt;/em&gt;&lt;em&gt; Growing Independent Research Efforts are Expanding Evidence Base Around How PEDMARK&lt;/em&gt;&lt;em&gt;®&lt;/em&gt;&lt;em&gt; (sodium thiosulfate injection) May Benefit Broader and More Diverse Patient Populations &lt;/em&gt;&lt;em&gt;~&lt;/em&gt;&lt;/p&gt;  &lt;p align=&quot;center&quot;&gt;&lt;em&gt;~ &lt;/em&gt;&lt;em&gt;Real-World Evidence Shows Administration of PEDMARK&lt;/em&gt;&lt;em&gt;®&lt;/em&gt;&lt;em&gt; Approximately Six Hours After Cisplatin Can Be Safe &amp;amp; Easily Integrated into Patient Care and Does Not Compromise Cisplatin’s Established Antitumor Activity &lt;/em&gt;&lt;em&gt;~&lt;/em&gt;&lt;/p&gt;  &lt;p align=&quot;justify&quot;&gt;RESEARCH TRIANGLE PARK, N.C., May  21, 2026  (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, today announced that new research evaluating PEDMARK® (sodium thiosulfate injection) across multiple patient populations and tumor types will be shared as</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/Fennec+Pharmaceuticals+Announces+New+Research+Supporting+Integration+and+Use+of+PEDMARK%C2%AE+at+the+2026+ASCO+Annual+Meeting/26537185.html</guid>
   <pubDate>Thu, 21 May 2026 18:01:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.06822034</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.17568519</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.50200982</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.50208664</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.50214646</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.50216726</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.60012004</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">FENC</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">FRX</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00081842</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00474218</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00786879</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.01304637</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.20026344</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.21047090</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.21157671</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.21612337</category>
   	  </item>
  <item>
   <title>Fennec Pharmaceuticals Announces New Research Supporting Integration and Use of PEDMARK® at the 2026 ASCO Annual Meeting</title>
   <link>http://www.streetinsider.com/Press+Releases/Fennec+Pharmaceuticals+Announces+New+Research+Supporting+Integration+and+Use+of+PEDMARK%C2%AE+at+the+2026+ASCO+Annual+Meeting/26537185.html</link>
   <description>
&lt;p align=&quot;center&quot;&gt;&lt;em&gt;~&lt;/em&gt;&lt;em&gt; Growing Independent Research Efforts are Expanding Evidence Base Around How PEDMARK&lt;/em&gt;&lt;em&gt;®&lt;/em&gt;&lt;em&gt; (sodium thiosulfate injection) May Benefit Broader and More Diverse Patient Populations &lt;/em&gt;&lt;em&gt;~&lt;/em&gt;&lt;/p&gt;  &lt;p align=&quot;center&quot;&gt;&lt;em&gt;~ &lt;/em&gt;&lt;em&gt;Real-World Evidence Shows Administration of PEDMARK&lt;/em&gt;&lt;em&gt;®&lt;/em&gt;&lt;em&gt; Approximately Six Hours After Cisplatin Can Be Safe &amp;amp; Easily Integrated into Patient Care and Does Not Compromise Cisplatin’s Established Antitumor Activity &lt;/em&gt;&lt;em&gt;~&lt;/em&gt;&lt;/p&gt;  &lt;p align=&quot;justify&quot;&gt;RESEARCH TRIANGLE PARK, N.C., May  21, 2026  (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, today announced that new research evaluating PEDMARK® (sodium thiosulfate injection) across multiple patient populations and tumor types will be shared as</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/Fennec+Pharmaceuticals+Announces+New+Research+Supporting+Integration+and+Use+of+PEDMARK%C2%AE+at+the+2026+ASCO+Annual+Meeting/26537185.html</guid>
   <pubDate>Thu, 21 May 2026 18:01:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.06822034</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.17568519</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.50200982</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.50208664</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.50214646</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.50216726</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.60012004</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">FENC</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">FRX</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00081842</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00474218</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00786879</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.01304637</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.20026344</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.21047090</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.21157671</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.21612337</category>
   	  </item>
  <item>
   <title>Fennec Pharmaceuticals Announces New Research Supporting Integration and Use of PEDMARK® at the 2026 ASCO Annual Meeting</title>
   <link>http://www.streetinsider.com/Press+Releases/Fennec+Pharmaceuticals+Announces+New+Research+Supporting+Integration+and+Use+of+PEDMARK%C2%AE+at+the+2026+ASCO+Annual+Meeting/26537185.html</link>
   <description>
&lt;p align=&quot;center&quot;&gt;&lt;em&gt;~&lt;/em&gt;&lt;em&gt; Growing Independent Research Efforts are Expanding Evidence Base Around How PEDMARK&lt;/em&gt;&lt;em&gt;®&lt;/em&gt;&lt;em&gt; (sodium thiosulfate injection) May Benefit Broader and More Diverse Patient Populations &lt;/em&gt;&lt;em&gt;~&lt;/em&gt;&lt;/p&gt;  &lt;p align=&quot;center&quot;&gt;&lt;em&gt;~ &lt;/em&gt;&lt;em&gt;Real-World Evidence Shows Administration of PEDMARK&lt;/em&gt;&lt;em&gt;®&lt;/em&gt;&lt;em&gt; Approximately Six Hours After Cisplatin Can Be Safe &amp;amp; Easily Integrated into Patient Care and Does Not Compromise Cisplatin’s Established Antitumor Activity &lt;/em&gt;&lt;em&gt;~&lt;/em&gt;&lt;/p&gt;  &lt;p align=&quot;justify&quot;&gt;RESEARCH TRIANGLE PARK, N.C., May  21, 2026  (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, today announced that new research evaluating PEDMARK® (sodium thiosulfate injection) across multiple patient populations and tumor types will be shared as</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/Fennec+Pharmaceuticals+Announces+New+Research+Supporting+Integration+and+Use+of+PEDMARK%C2%AE+at+the+2026+ASCO+Annual+Meeting/26537185.html</guid>
   <pubDate>Thu, 21 May 2026 18:01:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.06822034</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.17568519</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.50200982</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.50208664</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.50214646</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.50216726</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.60012004</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">FENC</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">FRX</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00081842</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00474218</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00786879</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.01304637</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.20026344</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.21047090</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.21157671</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.21612337</category>
   	  </item>
  <item>
   <title>Fennec Pharmaceuticals Announces New Research Supporting Integration and Use of PEDMARK® at the 2026 ASCO Annual Meeting</title>
   <link>http://www.streetinsider.com/Press+Releases/Fennec+Pharmaceuticals+Announces+New+Research+Supporting+Integration+and+Use+of+PEDMARK%C2%AE+at+the+2026+ASCO+Annual+Meeting/26537185.html</link>
   <description>
&lt;p align=&quot;center&quot;&gt;&lt;em&gt;~&lt;/em&gt;&lt;em&gt; Growing Independent Research Efforts are Expanding Evidence Base Around How PEDMARK&lt;/em&gt;&lt;em&gt;®&lt;/em&gt;&lt;em&gt; (sodium thiosulfate injection) May Benefit Broader and More Diverse Patient Populations &lt;/em&gt;&lt;em&gt;~&lt;/em&gt;&lt;/p&gt;  &lt;p align=&quot;center&quot;&gt;&lt;em&gt;~ &lt;/em&gt;&lt;em&gt;Real-World Evidence Shows Administration of PEDMARK&lt;/em&gt;&lt;em&gt;®&lt;/em&gt;&lt;em&gt; Approximately Six Hours After Cisplatin Can Be Safe &amp;amp; Easily Integrated into Patient Care and Does Not Compromise Cisplatin’s Established Antitumor Activity &lt;/em&gt;&lt;em&gt;~&lt;/em&gt;&lt;/p&gt;  &lt;p align=&quot;justify&quot;&gt;RESEARCH TRIANGLE PARK, N.C., May  21, 2026  (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, today announced that new research evaluating PEDMARK® (sodium thiosulfate injection) across multiple patient populations and tumor types will be shared as</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/Fennec+Pharmaceuticals+Announces+New+Research+Supporting+Integration+and+Use+of+PEDMARK%C2%AE+at+the+2026+ASCO+Annual+Meeting/26537185.html</guid>
   <pubDate>Thu, 21 May 2026 18:01:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.06822034</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.17568519</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.50200982</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.50208664</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.50214646</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.50216726</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.60012004</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">FENC</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">FRX</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00081842</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00474218</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00786879</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.01304637</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.20026344</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.21047090</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.21157671</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.21612337</category>
   	  </item>
  <item>
   <title>Fennec Pharmaceuticals Announces New Research Supporting Integration and Use of PEDMARK® at the 2026 ASCO Annual Meeting</title>
   <link>http://www.streetinsider.com/Press+Releases/Fennec+Pharmaceuticals+Announces+New+Research+Supporting+Integration+and+Use+of+PEDMARK%C2%AE+at+the+2026+ASCO+Annual+Meeting/26537185.html</link>
   <description>
&lt;p align=&quot;center&quot;&gt;&lt;em&gt;~&lt;/em&gt;&lt;em&gt; Growing Independent Research Efforts are Expanding Evidence Base Around How PEDMARK&lt;/em&gt;&lt;em&gt;®&lt;/em&gt;&lt;em&gt; (sodium thiosulfate injection) May Benefit Broader and More Diverse Patient Populations &lt;/em&gt;&lt;em&gt;~&lt;/em&gt;&lt;/p&gt;  &lt;p align=&quot;center&quot;&gt;&lt;em&gt;~ &lt;/em&gt;&lt;em&gt;Real-World Evidence Shows Administration of PEDMARK&lt;/em&gt;&lt;em&gt;®&lt;/em&gt;&lt;em&gt; Approximately Six Hours After Cisplatin Can Be Safe &amp;amp; Easily Integrated into Patient Care and Does Not Compromise Cisplatin’s Established Antitumor Activity &lt;/em&gt;&lt;em&gt;~&lt;/em&gt;&lt;/p&gt;  &lt;p align=&quot;justify&quot;&gt;RESEARCH TRIANGLE PARK, N.C., May  21, 2026  (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, today announced that new research evaluating PEDMARK® (sodium thiosulfate injection) across multiple patient populations and tumor types will be shared as</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/Fennec+Pharmaceuticals+Announces+New+Research+Supporting+Integration+and+Use+of+PEDMARK%C2%AE+at+the+2026+ASCO+Annual+Meeting/26537185.html</guid>
   <pubDate>Thu, 21 May 2026 18:01:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.06822034</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.17568519</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.50200982</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.50208664</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.50214646</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.50216726</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.60012004</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">FENC</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">FRX</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00081842</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00474218</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00786879</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.01304637</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.20026344</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.21047090</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.21157671</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.21612337</category>
   	  </item>
  <item>
   <title>Fennec Pharmaceuticals Announces New Research Supporting Integration and Use of PEDMARK® at the 2026 ASCO Annual Meeting</title>
   <link>http://www.streetinsider.com/Press+Releases/Fennec+Pharmaceuticals+Announces+New+Research+Supporting+Integration+and+Use+of+PEDMARK%C2%AE+at+the+2026+ASCO+Annual+Meeting/26537185.html</link>
   <description>
&lt;p align=&quot;center&quot;&gt;&lt;em&gt;~&lt;/em&gt;&lt;em&gt; Growing Independent Research Efforts are Expanding Evidence Base Around How PEDMARK&lt;/em&gt;&lt;em&gt;®&lt;/em&gt;&lt;em&gt; (sodium thiosulfate injection) May Benefit Broader and More Diverse Patient Populations &lt;/em&gt;&lt;em&gt;~&lt;/em&gt;&lt;/p&gt;  &lt;p align=&quot;center&quot;&gt;&lt;em&gt;~ &lt;/em&gt;&lt;em&gt;Real-World Evidence Shows Administration of PEDMARK&lt;/em&gt;&lt;em&gt;®&lt;/em&gt;&lt;em&gt; Approximately Six Hours After Cisplatin Can Be Safe &amp;amp; Easily Integrated into Patient Care and Does Not Compromise Cisplatin’s Established Antitumor Activity &lt;/em&gt;&lt;em&gt;~&lt;/em&gt;&lt;/p&gt;  &lt;p align=&quot;justify&quot;&gt;RESEARCH TRIANGLE PARK, N.C., May  21, 2026  (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, today announced that new research evaluating PEDMARK® (sodium thiosulfate injection) across multiple patient populations and tumor types will be shared as</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/Fennec+Pharmaceuticals+Announces+New+Research+Supporting+Integration+and+Use+of+PEDMARK%C2%AE+at+the+2026+ASCO+Annual+Meeting/26537185.html</guid>
   <pubDate>Thu, 21 May 2026 18:01:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.06822034</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.17568519</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.50200982</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.50208664</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.50214646</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.50216726</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.60012004</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">FENC</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">FRX</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00081842</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00474218</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00786879</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.01304637</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.20026344</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.21047090</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.21157671</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.21612337</category>
   	  </item>
  <item>
   <title>Fennec Pharmaceuticals Announces New Research Supporting Integration and Use of PEDMARK® at the 2026 ASCO Annual Meeting</title>
   <link>http://www.streetinsider.com/Press+Releases/Fennec+Pharmaceuticals+Announces+New+Research+Supporting+Integration+and+Use+of+PEDMARK%C2%AE+at+the+2026+ASCO+Annual+Meeting/26537185.html</link>
   <description>
&lt;p align=&quot;center&quot;&gt;&lt;em&gt;~&lt;/em&gt;&lt;em&gt; Growing Independent Research Efforts are Expanding Evidence Base Around How PEDMARK&lt;/em&gt;&lt;em&gt;®&lt;/em&gt;&lt;em&gt; (sodium thiosulfate injection) May Benefit Broader and More Diverse Patient Populations &lt;/em&gt;&lt;em&gt;~&lt;/em&gt;&lt;/p&gt;  &lt;p align=&quot;center&quot;&gt;&lt;em&gt;~ &lt;/em&gt;&lt;em&gt;Real-World Evidence Shows Administration of PEDMARK&lt;/em&gt;&lt;em&gt;®&lt;/em&gt;&lt;em&gt; Approximately Six Hours After Cisplatin Can Be Safe &amp;amp; Easily Integrated into Patient Care and Does Not Compromise Cisplatin’s Established Antitumor Activity &lt;/em&gt;&lt;em&gt;~&lt;/em&gt;&lt;/p&gt;  &lt;p align=&quot;justify&quot;&gt;RESEARCH TRIANGLE PARK, N.C., May  21, 2026  (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, today announced that new research evaluating PEDMARK® (sodium thiosulfate injection) across multiple patient populations and tumor types will be shared as</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/Fennec+Pharmaceuticals+Announces+New+Research+Supporting+Integration+and+Use+of+PEDMARK%C2%AE+at+the+2026+ASCO+Annual+Meeting/26537185.html</guid>
   <pubDate>Thu, 21 May 2026 18:01:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.06822034</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.17568519</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.50200982</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.50208664</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.50214646</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.50216726</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.60012004</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">FENC</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">FRX</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00081842</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00474218</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00786879</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.01304637</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.20026344</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.21047090</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.21157671</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.21612337</category>
   	  </item>
  <item>
   <title>Fennec Pharmaceuticals Announces New Research Supporting Integration and Use of PEDMARK® at the 2026 ASCO Annual Meeting</title>
   <link>http://www.streetinsider.com/Press+Releases/Fennec+Pharmaceuticals+Announces+New+Research+Supporting+Integration+and+Use+of+PEDMARK%C2%AE+at+the+2026+ASCO+Annual+Meeting/26537185.html</link>
   <description>
&lt;p align=&quot;center&quot;&gt;&lt;em&gt;~&lt;/em&gt;&lt;em&gt; Growing Independent Research Efforts are Expanding Evidence Base Around How PEDMARK&lt;/em&gt;&lt;em&gt;®&lt;/em&gt;&lt;em&gt; (sodium thiosulfate injection) May Benefit Broader and More Diverse Patient Populations &lt;/em&gt;&lt;em&gt;~&lt;/em&gt;&lt;/p&gt;  &lt;p align=&quot;center&quot;&gt;&lt;em&gt;~ &lt;/em&gt;&lt;em&gt;Real-World Evidence Shows Administration of PEDMARK&lt;/em&gt;&lt;em&gt;®&lt;/em&gt;&lt;em&gt; Approximately Six Hours After Cisplatin Can Be Safe &amp;amp; Easily Integrated into Patient Care and Does Not Compromise Cisplatin’s Established Antitumor Activity &lt;/em&gt;&lt;em&gt;~&lt;/em&gt;&lt;/p&gt;  &lt;p align=&quot;justify&quot;&gt;RESEARCH TRIANGLE PARK, N.C., May  21, 2026  (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, today announced that new research evaluating PEDMARK® (sodium thiosulfate injection) across multiple patient populations and tumor types will be shared as</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Press+Releases/Fennec+Pharmaceuticals+Announces+New+Research+Supporting+Integration+and+Use+of+PEDMARK%C2%AE+at+the+2026+ASCO+Annual+Meeting/26537185.html</guid>
   <pubDate>Thu, 21 May 2026 18:01:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.06822034</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.17568519</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.50200982</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.50208664</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.50214646</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.50216726</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.60012004</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">FENC</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">FRX</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00081842</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00474218</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00786879</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.01304637</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.20026344</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.21047090</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.21157671</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.21612337</category>
   	  </item>
  <item>
   <title>Fennec Pharmaceuticals Announces New Research Supporting Integration and Use of PEDMARK® at the 2026 ASCO Annual Meeting</title>
   <link>http://www.streetinsider.com/Globe+Newswire/Fennec+Pharmaceuticals+Announces+New+Research+Supporting+Integration+and+Use+of+PEDMARK%C2%AE+at+the+2026+ASCO+Annual+Meeting/26537185.html</link>
   <description>
&lt;p align=&quot;center&quot;&gt;&lt;em&gt;~&lt;/em&gt;&lt;em&gt; Growing Independent Research Efforts are Expanding Evidence Base Around How PEDMARK&lt;/em&gt;&lt;em&gt;®&lt;/em&gt;&lt;em&gt; (sodium thiosulfate injection) May Benefit Broader and More Diverse Patient Populations &lt;/em&gt;&lt;em&gt;~&lt;/em&gt;&lt;/p&gt;  &lt;p align=&quot;center&quot;&gt;&lt;em&gt;~ &lt;/em&gt;&lt;em&gt;Real-World Evidence Shows Administration of PEDMARK&lt;/em&gt;&lt;em&gt;®&lt;/em&gt;&lt;em&gt; Approximately Six Hours After Cisplatin Can Be Safe &amp;amp; Easily Integrated into Patient Care and Does Not Compromise Cisplatin’s Established Antitumor Activity &lt;/em&gt;&lt;em&gt;~&lt;/em&gt;&lt;/p&gt;  &lt;p align=&quot;justify&quot;&gt;RESEARCH TRIANGLE PARK, N.C., May  21, 2026  (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, today announced that new research evaluating PEDMARK® (sodium thiosulfate injection) across multiple patient populations and tumor types will be shared as</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Globe+Newswire/Fennec+Pharmaceuticals+Announces+New+Research+Supporting+Integration+and+Use+of+PEDMARK%C2%AE+at+the+2026+ASCO+Annual+Meeting/26537185.html</guid>
   <pubDate>Thu, 21 May 2026 18:01:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.06822034</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.17568519</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.50200982</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.50208664</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.50214646</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.50216726</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.60012004</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">FENC</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">FRX</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00081842</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00474218</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00786879</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.01304637</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.20026344</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.21047090</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.21157671</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.21612337</category>
   	  </item>
  <item>
   <title>Fennec Pharmaceuticals Announces New Research Supporting Integration and Use of PEDMARK® at the 2026 ASCO Annual Meeting</title>
   <link>http://www.streetinsider.com/Globe+Newswire/Fennec+Pharmaceuticals+Announces+New+Research+Supporting+Integration+and+Use+of+PEDMARK%C2%AE+at+the+2026+ASCO+Annual+Meeting/26537185.html</link>
   <description>
&lt;p align=&quot;center&quot;&gt;&lt;em&gt;~&lt;/em&gt;&lt;em&gt; Growing Independent Research Efforts are Expanding Evidence Base Around How PEDMARK&lt;/em&gt;&lt;em&gt;®&lt;/em&gt;&lt;em&gt; (sodium thiosulfate injection) May Benefit Broader and More Diverse Patient Populations &lt;/em&gt;&lt;em&gt;~&lt;/em&gt;&lt;/p&gt;  &lt;p align=&quot;center&quot;&gt;&lt;em&gt;~ &lt;/em&gt;&lt;em&gt;Real-World Evidence Shows Administration of PEDMARK&lt;/em&gt;&lt;em&gt;®&lt;/em&gt;&lt;em&gt; Approximately Six Hours After Cisplatin Can Be Safe &amp;amp; Easily Integrated into Patient Care and Does Not Compromise Cisplatin’s Established Antitumor Activity &lt;/em&gt;&lt;em&gt;~&lt;/em&gt;&lt;/p&gt;  &lt;p align=&quot;justify&quot;&gt;RESEARCH TRIANGLE PARK, N.C., May  21, 2026  (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, today announced that new research evaluating PEDMARK® (sodium thiosulfate injection) across multiple patient populations and tumor types will be shared as</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Globe+Newswire/Fennec+Pharmaceuticals+Announces+New+Research+Supporting+Integration+and+Use+of+PEDMARK%C2%AE+at+the+2026+ASCO+Annual+Meeting/26537185.html</guid>
   <pubDate>Thu, 21 May 2026 18:01:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.06822034</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.17568519</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.50200982</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.50208664</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.50214646</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.50216726</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.60012004</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">FENC</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">FRX</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00081842</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00474218</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00786879</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.01304637</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.20026344</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.21047090</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.21157671</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.21612337</category>
   	  </item>
  <item>
   <title>Fennec Pharmaceuticals Announces New Research Supporting Integration and Use of PEDMARK® at the 2026 ASCO Annual Meeting</title>
   <link>http://www.streetinsider.com/Globe+Newswire/Fennec+Pharmaceuticals+Announces+New+Research+Supporting+Integration+and+Use+of+PEDMARK%C2%AE+at+the+2026+ASCO+Annual+Meeting/26537185.html</link>
   <description>
&lt;p align=&quot;center&quot;&gt;&lt;em&gt;~&lt;/em&gt;&lt;em&gt; Growing Independent Research Efforts are Expanding Evidence Base Around How PEDMARK&lt;/em&gt;&lt;em&gt;®&lt;/em&gt;&lt;em&gt; (sodium thiosulfate injection) May Benefit Broader and More Diverse Patient Populations &lt;/em&gt;&lt;em&gt;~&lt;/em&gt;&lt;/p&gt;  &lt;p align=&quot;center&quot;&gt;&lt;em&gt;~ &lt;/em&gt;&lt;em&gt;Real-World Evidence Shows Administration of PEDMARK&lt;/em&gt;&lt;em&gt;®&lt;/em&gt;&lt;em&gt; Approximately Six Hours After Cisplatin Can Be Safe &amp;amp; Easily Integrated into Patient Care and Does Not Compromise Cisplatin’s Established Antitumor Activity &lt;/em&gt;&lt;em&gt;~&lt;/em&gt;&lt;/p&gt;  &lt;p align=&quot;justify&quot;&gt;RESEARCH TRIANGLE PARK, N.C., May  21, 2026  (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, today announced that new research evaluating PEDMARK® (sodium thiosulfate injection) across multiple patient populations and tumor types will be shared as</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Globe+Newswire/Fennec+Pharmaceuticals+Announces+New+Research+Supporting+Integration+and+Use+of+PEDMARK%C2%AE+at+the+2026+ASCO+Annual+Meeting/26537185.html</guid>
   <pubDate>Thu, 21 May 2026 18:01:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.06822034</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.17568519</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.50200982</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.50208664</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.50214646</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.50216726</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.60012004</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">FENC</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">FRX</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00081842</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00474218</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00786879</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.01304637</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.20026344</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.21047090</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.21157671</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.21612337</category>
   	  </item>
  <item>
   <title>Fennec Pharmaceuticals Announces New Research Supporting Integration and Use of PEDMARK® at the 2026 ASCO Annual Meeting</title>
   <link>http://www.streetinsider.com/Globe+Newswire/Fennec+Pharmaceuticals+Announces+New+Research+Supporting+Integration+and+Use+of+PEDMARK%C2%AE+at+the+2026+ASCO+Annual+Meeting/26537185.html</link>
   <description>
&lt;p align=&quot;center&quot;&gt;&lt;em&gt;~&lt;/em&gt;&lt;em&gt; Growing Independent Research Efforts are Expanding Evidence Base Around How PEDMARK&lt;/em&gt;&lt;em&gt;®&lt;/em&gt;&lt;em&gt; (sodium thiosulfate injection) May Benefit Broader and More Diverse Patient Populations &lt;/em&gt;&lt;em&gt;~&lt;/em&gt;&lt;/p&gt;  &lt;p align=&quot;center&quot;&gt;&lt;em&gt;~ &lt;/em&gt;&lt;em&gt;Real-World Evidence Shows Administration of PEDMARK&lt;/em&gt;&lt;em&gt;®&lt;/em&gt;&lt;em&gt; Approximately Six Hours After Cisplatin Can Be Safe &amp;amp; Easily Integrated into Patient Care and Does Not Compromise Cisplatin’s Established Antitumor Activity &lt;/em&gt;&lt;em&gt;~&lt;/em&gt;&lt;/p&gt;  &lt;p align=&quot;justify&quot;&gt;RESEARCH TRIANGLE PARK, N.C., May  21, 2026  (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, today announced that new research evaluating PEDMARK® (sodium thiosulfate injection) across multiple patient populations and tumor types will be shared as</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Globe+Newswire/Fennec+Pharmaceuticals+Announces+New+Research+Supporting+Integration+and+Use+of+PEDMARK%C2%AE+at+the+2026+ASCO+Annual+Meeting/26537185.html</guid>
   <pubDate>Thu, 21 May 2026 18:01:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.06822034</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.17568519</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.50200982</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.50208664</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.50214646</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.50216726</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.60012004</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">FENC</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">FRX</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00081842</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00474218</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00786879</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.01304637</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.20026344</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.21047090</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.21157671</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.21612337</category>
   	  </item>
  <item>
   <title>Fennec Pharmaceuticals Announces New Research Supporting Integration and Use of PEDMARK® at the 2026 ASCO Annual Meeting</title>
   <link>http://www.streetinsider.com/Globe+Newswire/Fennec+Pharmaceuticals+Announces+New+Research+Supporting+Integration+and+Use+of+PEDMARK%C2%AE+at+the+2026+ASCO+Annual+Meeting/26537185.html</link>
   <description>
&lt;p align=&quot;center&quot;&gt;&lt;em&gt;~&lt;/em&gt;&lt;em&gt; Growing Independent Research Efforts are Expanding Evidence Base Around How PEDMARK&lt;/em&gt;&lt;em&gt;®&lt;/em&gt;&lt;em&gt; (sodium thiosulfate injection) May Benefit Broader and More Diverse Patient Populations &lt;/em&gt;&lt;em&gt;~&lt;/em&gt;&lt;/p&gt;  &lt;p align=&quot;center&quot;&gt;&lt;em&gt;~ &lt;/em&gt;&lt;em&gt;Real-World Evidence Shows Administration of PEDMARK&lt;/em&gt;&lt;em&gt;®&lt;/em&gt;&lt;em&gt; Approximately Six Hours After Cisplatin Can Be Safe &amp;amp; Easily Integrated into Patient Care and Does Not Compromise Cisplatin’s Established Antitumor Activity &lt;/em&gt;&lt;em&gt;~&lt;/em&gt;&lt;/p&gt;  &lt;p align=&quot;justify&quot;&gt;RESEARCH TRIANGLE PARK, N.C., May  21, 2026  (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, today announced that new research evaluating PEDMARK® (sodium thiosulfate injection) across multiple patient populations and tumor types will be shared as</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Globe+Newswire/Fennec+Pharmaceuticals+Announces+New+Research+Supporting+Integration+and+Use+of+PEDMARK%C2%AE+at+the+2026+ASCO+Annual+Meeting/26537185.html</guid>
   <pubDate>Thu, 21 May 2026 18:01:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.06822034</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.17568519</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.50200982</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.50208664</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.50214646</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.50216726</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.60012004</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">FENC</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">FRX</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00081842</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00474218</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00786879</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.01304637</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.20026344</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.21047090</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.21157671</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.21612337</category>
   	  </item>
  <item>
   <title>Fennec Pharmaceuticals Announces New Research Supporting Integration and Use of PEDMARK® at the 2026 ASCO Annual Meeting</title>
   <link>http://www.streetinsider.com/Globe+Newswire/Fennec+Pharmaceuticals+Announces+New+Research+Supporting+Integration+and+Use+of+PEDMARK%C2%AE+at+the+2026+ASCO+Annual+Meeting/26537185.html</link>
   <description>
&lt;p align=&quot;center&quot;&gt;&lt;em&gt;~&lt;/em&gt;&lt;em&gt; Growing Independent Research Efforts are Expanding Evidence Base Around How PEDMARK&lt;/em&gt;&lt;em&gt;®&lt;/em&gt;&lt;em&gt; (sodium thiosulfate injection) May Benefit Broader and More Diverse Patient Populations &lt;/em&gt;&lt;em&gt;~&lt;/em&gt;&lt;/p&gt;  &lt;p align=&quot;center&quot;&gt;&lt;em&gt;~ &lt;/em&gt;&lt;em&gt;Real-World Evidence Shows Administration of PEDMARK&lt;/em&gt;&lt;em&gt;®&lt;/em&gt;&lt;em&gt; Approximately Six Hours After Cisplatin Can Be Safe &amp;amp; Easily Integrated into Patient Care and Does Not Compromise Cisplatin’s Established Antitumor Activity &lt;/em&gt;&lt;em&gt;~&lt;/em&gt;&lt;/p&gt;  &lt;p align=&quot;justify&quot;&gt;RESEARCH TRIANGLE PARK, N.C., May  21, 2026  (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, today announced that new research evaluating PEDMARK® (sodium thiosulfate injection) across multiple patient populations and tumor types will be shared as</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Globe+Newswire/Fennec+Pharmaceuticals+Announces+New+Research+Supporting+Integration+and+Use+of+PEDMARK%C2%AE+at+the+2026+ASCO+Annual+Meeting/26537185.html</guid>
   <pubDate>Thu, 21 May 2026 18:01:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.06822034</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.17568519</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.50200982</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.50208664</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.50214646</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.50216726</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.60012004</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">FENC</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">FRX</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00081842</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00474218</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00786879</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.01304637</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.20026344</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.21047090</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.21157671</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.21612337</category>
   	  </item>
  <item>
   <title>Fennec Pharmaceuticals Announces New Research Supporting Integration and Use of PEDMARK® at the 2026 ASCO Annual Meeting</title>
   <link>http://www.streetinsider.com/Globe+Newswire/Fennec+Pharmaceuticals+Announces+New+Research+Supporting+Integration+and+Use+of+PEDMARK%C2%AE+at+the+2026+ASCO+Annual+Meeting/26537185.html</link>
   <description>
&lt;p align=&quot;center&quot;&gt;&lt;em&gt;~&lt;/em&gt;&lt;em&gt; Growing Independent Research Efforts are Expanding Evidence Base Around How PEDMARK&lt;/em&gt;&lt;em&gt;®&lt;/em&gt;&lt;em&gt; (sodium thiosulfate injection) May Benefit Broader and More Diverse Patient Populations &lt;/em&gt;&lt;em&gt;~&lt;/em&gt;&lt;/p&gt;  &lt;p align=&quot;center&quot;&gt;&lt;em&gt;~ &lt;/em&gt;&lt;em&gt;Real-World Evidence Shows Administration of PEDMARK&lt;/em&gt;&lt;em&gt;®&lt;/em&gt;&lt;em&gt; Approximately Six Hours After Cisplatin Can Be Safe &amp;amp; Easily Integrated into Patient Care and Does Not Compromise Cisplatin’s Established Antitumor Activity &lt;/em&gt;&lt;em&gt;~&lt;/em&gt;&lt;/p&gt;  &lt;p align=&quot;justify&quot;&gt;RESEARCH TRIANGLE PARK, N.C., May  21, 2026  (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, today announced that new research evaluating PEDMARK® (sodium thiosulfate injection) across multiple patient populations and tumor types will be shared as</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Globe+Newswire/Fennec+Pharmaceuticals+Announces+New+Research+Supporting+Integration+and+Use+of+PEDMARK%C2%AE+at+the+2026+ASCO+Annual+Meeting/26537185.html</guid>
   <pubDate>Thu, 21 May 2026 18:01:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.06822034</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.17568519</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.50200982</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.50208664</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.50214646</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.50216726</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.60012004</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">FENC</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">FRX</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00081842</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00474218</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00786879</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.01304637</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.20026344</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.21047090</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.21157671</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.21612337</category>
   	  </item>
  <item>
   <title>Fennec Pharmaceuticals Announces New Research Supporting Integration and Use of PEDMARK® at the 2026 ASCO Annual Meeting</title>
   <link>http://www.streetinsider.com/Globe+Newswire/Fennec+Pharmaceuticals+Announces+New+Research+Supporting+Integration+and+Use+of+PEDMARK%C2%AE+at+the+2026+ASCO+Annual+Meeting/26537185.html</link>
   <description>
&lt;p align=&quot;center&quot;&gt;&lt;em&gt;~&lt;/em&gt;&lt;em&gt; Growing Independent Research Efforts are Expanding Evidence Base Around How PEDMARK&lt;/em&gt;&lt;em&gt;®&lt;/em&gt;&lt;em&gt; (sodium thiosulfate injection) May Benefit Broader and More Diverse Patient Populations &lt;/em&gt;&lt;em&gt;~&lt;/em&gt;&lt;/p&gt;  &lt;p align=&quot;center&quot;&gt;&lt;em&gt;~ &lt;/em&gt;&lt;em&gt;Real-World Evidence Shows Administration of PEDMARK&lt;/em&gt;&lt;em&gt;®&lt;/em&gt;&lt;em&gt; Approximately Six Hours After Cisplatin Can Be Safe &amp;amp; Easily Integrated into Patient Care and Does Not Compromise Cisplatin’s Established Antitumor Activity &lt;/em&gt;&lt;em&gt;~&lt;/em&gt;&lt;/p&gt;  &lt;p align=&quot;justify&quot;&gt;RESEARCH TRIANGLE PARK, N.C., May  21, 2026  (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company, today announced that new research evaluating PEDMARK® (sodium thiosulfate injection) across multiple patient populations and tumor types will be shared as</description>
   <guid isPermaLink="true">http://www.streetinsider.com/Globe+Newswire/Fennec+Pharmaceuticals+Announces+New+Research+Supporting+Integration+and+Use+of+PEDMARK%C2%AE+at+the+2026+ASCO+Annual+Meeting/26537185.html</guid>
   <pubDate>Thu, 21 May 2026 18:01:00 -0400</pubDate>
      	<category domain="http://rss.financialcontent.com/stocksymbol">A.06822034</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.17568519</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.50200982</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.50208664</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.50214646</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.50216726</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">A.60012004</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">FENC</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">FRX</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00081842</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00474218</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.00786879</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.01304637</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.20026344</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.21047090</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.21157671</category>
   	   	<category domain="http://rss.financialcontent.com/stocksymbol">O.21612337</category>
   	  </item>
 </channel>
</rss>
